UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 1, 2007

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, or a non-accelerated filer. See

definition of "accelerated filer and large accelerated filer" in

Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer X

Accelerated filer Non-accelerated

filer

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At May 1, 2007, 7,018,262,990 shares of the issuer's

voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

April 1, 2007

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements

Condensed

Consolidated Statements of Income for the three months ended April 1, 2007,

and April 2, 2006

Condensed

Consolidated Balance Sheets as of April 1, 2007, and December 31, 2006

Condensed

Consolidated Statements of Cash Flows for the three months ended April 1,

2007, and April 2, 2006

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

17

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

18

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

43

Item 4.

Controls and

Procedures

43

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

43

Item 1A.

Risk Factors

46

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

46

Item 3.

Defaults Upon

Senior Securities

46

Item 4.

Submission of

Matters to a Vote of Security Holders

47

Item 5.

Other

Information

48

Item 6.

Exhibits

48

Signature

49

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three

Months Ended

(millions, except per common share

data)

April 1,

2007

April 2,

2006

Revenues

12,474

11,747

Costs and expenses:

Cost of sales(a)

1,887

1,671

Selling,

informational and administrative expenses(a)

3,361

3,395

Research and

development expenses(a)

1,665

1,543

Amortization of

intangible assets

815

825

Acquisition-related

in-process research and development charges

283

--

Restructuring

charges and acquisition-related costs

812

299

Other (income)/deductions - net

(402)

(256)

Income from

continuing operations before provision for taxes on income and minority

interests

4,053

4,270

Provision for

taxes on income

689

262

Minority

interests

Income from

continuing operations

3,361

4,006

Discontinued

operations:

Income from

discontinued operations - net of tax

--

102

Gains on sales

of discontinued operations - net of tax

31

Discontinued

operations - net of tax

31

105

Net income

3,392

4,111

Earnings per common share - basic:

Income from

continuing operations

0.48

0.55

Discontinued

operations - net of tax

--

0.01

Net income

0.48

0.56

Earnings per common share -

diluted:

Income from

continuing operations

0.48

0.55

Discontinued

operations - net of tax

--

0.01

Net income

0.48

0.56

Weighted-average

shares used to calculate earnings per common share:

Basic

7,051

7,314

Diluted

7,075

7,348

Cash dividends paid per common

share

0.29

0.24

(a)

Exclusive of amortization of

intangible assets, except as disclosed in Note 10B. Goodwill and

Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

April 1,

2007*

Dec. 31,

2006**

ASSETS

Cash and cash equivalents

2,492

1,827

Short-term investments

19,978

25,886

Accounts receivable, less allowance

for doubtful accounts

10,455

9,392

Short-term loans

462

514

Inventories

5,694

6,111

Prepaid expenses and taxes

3,231

3,157

Assets of discontinued operations and

other assets held for sale

25

62

Total current assets

42,337

46,949

Long-term

investments and loans

4,817

3,892

Property, plant and equipment, less

accumulated depreciation

16,481

16,632

Goodwill

20,911

20,876

Identifiable

intangible assets, less accumulated amortization

23,501

24,350

Other assets,

deferred taxes and deferred charges

2,436

2,138

Total assets

110,483

114,837

LIABILITIES

AND SHAREHOLDERS' EQUITY

Short-term borrowings, including

current portion of long-term debt

2,638

2,434

Accounts payable

2,037

2,019

Dividends payable

2,055

Income taxes payable

533

6,466

Accrued compensation and related

items

1,679

1,903

Other current liabilities

6,412

6,510

Liabilities of discontinued operations

and other liabilities held for sale

--

Total current liabilities

13,301

21,389

Long-term debt

4,771

5,546

Pension benefit

obligations

3,387

3,632

Postretirement

benefit obligations

1,967

1,970

Deferred taxes

7,363

8,015

Other taxes

payable

4,568

--

Other

noncurrent liabilities

2,638

2,927

Total liabilities

37,995

43,479

Shareholders' Equity

Preferred stock

124

141

Common stock

441

441

Additional

paid-in capital

69,209

69,104

Employee

benefit trust, at fair value

(583)

(788)

Treasury stock

(49,255)

(46,740)

Retained

earnings

53,063

49,669

Accumulated

other comprehensive income

(511)

(469)

Total shareholders' equity

72,488

71,358

Total liabilities and shareholders'

equity

110,483

114,837

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three

Months Ended

(millions of dollars)

April 1,

2007

April 2,

2006

Operating

Activities:

Net income

3,392

4,111

Adjustments to

reconcile net income to net cash provided by operating activities:

Depreciation

and amortization

1,271

1,351

Share-based

compensation expense

141

172

Acquisition-related

in-process research and development charges

283

--

Gains on

disposal of investments, products and product lines

(10)

(77)

Income from

discontinued operations

--

155

Gains on sales

of discontinued operations

(40)

(5)

Deferred taxes

from continuing operations

(268)

(309)

Other deferred

taxes

--

(5)

Other non-cash

adjustments

61

26

Changes in

assets and liabilities (net of businesses acquired and divested)

(3,587)

(1,458)

Net cash provided by operating

activities

1,243

3,961

Investing Activities:

Purchases of

property, plant and equipment

(329)

(418)

Purchases of

short-term investments

(5,617)

(2,735)

Proceeds from

redemptions of short-term investments

11,819

10,438

Purchases of

long-term investments

(1,158)

(216)

Proceeds from redemptions

of long-term investments

Purchases of other

assets

(2)

(35)

Proceeds from

sales of other assets

--

Proceeds from

the sales of businesses, products and product lines

Acquisitions,

net of cash acquired

(463)

(1,440)

Other investing

activities

(177)

Net cash provided by investing

activities

4,271

5,431

Financing Activities:

Increase in

short-term borrowings, net

162

826

Principal

payments on short-term borrowings

(729)

(8,056)

Proceeds from

issuances of long-term debt

19

1,035

Principal

payments on long-term debt

(58)

(1)

Purchases of

common stock

(2,500)

(1,000)

Cash dividends

paid

(2,032)

(1,743)

Stock option

transactions and other

290

173

Net cash used

in financing activities

(4,848)

(8,766)

Effect of exchange-rate

changes on cash and cash equivalents

(1)

(4)

Net increase/(decrease)

in cash and cash equivalents

665

622

Cash and cash

equivalents at beginning of period

1,827

2,247

Cash and cash

equivalents at end of period

2,492

2,869

Supplemental

Cash Flow Information:

Cash paid

during the period for:

Income taxes

2,424

640

Interest

170

213

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of

Presentation

We prepared the condensed

consolidated financial statements following the requirements of the Securities

and Exchange Commission (SEC) for interim reporting. As permitted under those

rules, certain footnotes or other financial information that are normally

required by accounting principles generally accepted in the United States of

America (GAAP) can be condensed or omitted. Balance sheet amounts and operating

results for subsidiaries operating outside the U.S. are as of and for the

three-month periods ended February 25, 2007, and February 26, 2006.

We made certain reclassifications to

the 2006 condensed consolidated financial statements to conform to the 2007 presentation.

These reclassifications are primarily related to discontinued operations (see Note

4. Discontinued Operations).

Revenues, expenses, assets and

liabilities can vary during each quarter of the year. Therefore, the results

and trends in these interim financial statements may not be representative of

those for the full year.

We are responsible for the unaudited

financial statements included in this document. The financial statements

include all normal and recurring adjustments that are considered necessary for

the fair presentation of our financial position and operating results.

The information included in this

Quarterly Report on Form 10-Q should be read in conjunction with the

consolidated financial statements and accompanying notes included in Pfizer's

Annual Report on Form 10-K for the year ended December 31, 2006.

Note 2. Adoption of New

Accounting Policy

As of January 1, 2007, we adopted the provisions of Financial Accounting

Standards Board (FASB) Interpretation No. 48 (FIN 48), Accounting for

Uncertainty in Income Taxes, an interpretation of SFAS 109, Accounting for

Income Taxes, and changed our policy related to the accounting for

income tax contingencies. To understand the cumulative effect of this

accounting change, see Note 6A. Taxes on Income: Adoption of

New Accounting Standard.

We continue to account for income tax

contingencies using a benefit recognition model. Beginning January

1, 2007, if we consider that a tax position is 'more likely than not' of being

sustained upon audit, based solely on the technical merits of the position, we

recognize the benefit. We measure the benefit by determining the amount that is

greater than 50% likely of being realized upon settlement, presuming that the

tax position is examined by the appropriate taxing authority that has full

knowledge of all relevant information. These assessments can be complex and we

often obtain assistance from external advisors.

Under the benefit recognition model, if our initial assessment

fails to result in the recognition of a tax benefit, we regularly monitor our

position and subsequently recognize the tax benefit if there are changes in tax

law or analogous case law that sufficiently raise the likelihood of prevailing

on the technical merits of the position to more likely than not; if the statute

of limitations expires; or if there is a completion of an audit resulting in a

settlement of that tax year with the appropriate agency.

Uncertain tax positions, represented by liabilities on our balance sheet,

are now classified as current only when we expect to pay cash within the next

12 months. Interest and penalties, if any, continue to be recorded in Provision

for taxes on income and are classified on the balance sheet with the

related tax liability.

Historically, our policy had been to account for income tax contingencies

based on whether we determined our tax position to be 'probable' under current

tax law of being sustained, as well as an analysis of potential outcomes under

a given set of facts and circumstances. In addition, we previously

considered all tax liabilities as current once the associated tax year was

under audit.

Note 3. Acquisitions

In the first quarter of 2007, we

acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical

company with a number of diabetes candidates and a novel technology platform

for developing new protein drug candidates, and Embrex, Inc., an animal health

company that possesses a unique vaccine delivery system known as Inovoject, which

enables baby chicks to be vaccinated while inside their eggs. In connection

with these and other small acquisitions, we recorded $283 million in Acquisition-related

in-process research and development charges.

On February 28, 2006, we completed

the acquisition of the sanofi-aventis worldwide rights, including patent rights

and production technology, to manufacture and sell Exubera, an inhaled form of

insulin for use in adults with type 1 and type 2 diabetes, and the

insulin-production business and facilities located in Frankfurt, Germany,

previously jointly owned by Pfizer and sanofi-aventis, for approximately $1.4 billion

(including transaction costs). In 2006, in connection with the acquisition, as

part of our final purchase price allocation, we recorded $1.0 billion of

developed technology rights, $218 million of inventory and $166 million

of Goodwill, all of which have been allocated to our Pharmaceutical segment.

The amortization of the developed technology rights is primarily included in Cost

of sales. Prior to the acquisition, in connection with our collaboration

agreement with sanofi-aventis, we recorded a research and development milestone

due to us from sanofi-aventis of $118 million ($71 million, after

tax) in the first quarter of 2006 in Research and development expenses

upon the approval of Exubera in January 2006 by the Food and Drug

Administration (FDA).

Note 4. Discontinued

Operations

The following amounts, primarily related

to our Consumer Healthcare business which was sold in December 2006 for $16.6 billion,

have been segregated from continuing operations and included in Discontinued

operations - net of tax in the condensed consolidated statements of income:

First

Quarter

(in millions)

April 1,

2007

April 2,

2006

Revenues

--

919

Pre-tax income

--

155

Provision for

taxes on income

--

(53)

Income from operations

of discontinued businesses - net of tax

--

102

Pre-tax gains on sales of

discontinued businesses

40

Provision for taxes on gains

(9)

(2)

Gains on sales

of discontinued operations - net of tax

31

Discontinued operations - net of

tax

31

105

For a period of time, we will

continue to generate cash flows and to report income statement activity in

continuing operations that are associated with our former Consumer Healthcare

business. The activities that give rise to these impacts are transitional in

nature and generally result from agreements that ensure and facilitate the

orderly transfer of business operations to the new owner. Included in

continuing operations for the first quarter of 2007 are the following amounts

associated with these transition service agreements that will no longer occur

after the full transfer of activities to the new owner: Revenues ($44 million),

Cost of sales ($35 million), Selling, informational and

administrative expense ($2 million) and Other

(income)/deduction-net ($2 million income).

Note 5. Adapting to

Scale Productivity Initiative

We incurred the following costs in

connection with our Adapting to Scale (AtS) productivity initiative, which was launched

in early 2005 and broadened in October 2006:

First

Quarter

(millions

of dollars)

April 1,

2007

April 2,

2006

Implementation

costs(a)

174

185

Restructuring

charges(b)

795

294

Total AtS costs

969

479

(a)

For

the first quarter of 2007, included in Cost of sales ($94 million),

Selling, informational and administrative expenses ($49 million),

and Research and development expenses ($31 million). For

the first quarter of 2006, included in Cost of sales ($124 million),

Selling, informational and administrative expenses ($39 million) and

Research and development expenses ($22 million).

(b)

Included

in Restructuring charges and acquisition-related costs.

Through April 1, 2007, the

restructuring charges primarily relate to our plant network optimization

efforts and the restructuring of our U.S. marketing and worldwide research and

development operations, while the implementation costs primarily relate to system

and process standardization, as well as the expansion of shared services.

The components of restructuring charges

associated with AtS follow:

(millions

of dollars)

Costs

Incurred

Through

April 1,

2007

Utilization

Through

April 1,

2007

Accrual

as of

April 1,

2007

(a)

Employee

termination costs

1,843

1,154

689

Asset

impairments

513

513

Other

173

107

66

Total

2,529

1,774

755

(a)

Included

in Other current liabilities and Other noncurrent liabilities.

During the first quarter of 2007, we

expensed $731 million for Employee termination costs, $23 million

for Asset impairments and $41 million in Other. Through April 1,

2007, Employee termination costs represent the expected reduction

of the workforce by 13,568 employees, mainly in research, manufacturing

and sales. Approximately 8,510 employees were terminated as of April 1,

2007. Employee termination costs include accrued severance benefits,

pension and postretirement benefits. Asset impairments primarily include

charges to write down property, plant and equipment. Other primarily

includes costs to exit certain activities.

Note 6. Taxes on

Income

A. Adoption of New Accounting Standard

As of January 1, 2007, we adopted the provisions of FIN 48, Accounting

for Uncertainty in Income Taxes, an interpretation of SFAS 109, Accounting

for Income Taxes. See Note 2. Adoption of New Accounting Policy,

for a full description of our accounting policy related to the accounting for

income tax contingencies. As a result of the

implementation of FIN 48, we reduced our existing liabilities for uncertain tax

positions by approximately $11 million, which has been recorded as a

direct adjustment to the opening balance of Retained earnings, and changed

the classification of virtually all uncertain tax positions, including the

associated accrued interest, from current to noncurrent.

B. Taxes on Income

On January 23, 2006, the Internal

Revenue Service (IRS) issued final regulations on Statutory Mergers and

Consolidations, which impacted certain prior-period transactions. In the first

quarter of 2006, we recorded a tax benefit of $217 million, reflecting the

total impact of these regulations.

On January 25, 2006, we were notified by the IRS Appeals Division that a

resolution had been reached on the matter that we were in the process of

appealing related to the tax deductibility of an acquisition-related breakup

fee paid by Warner-Lambert Company in 2000. As a result, in the first quarter

of 2006, we recorded a tax benefit of approximately $441 million related

to the resolution of this issue.